AB2 Bio signs U.S. option and licensing agreement with Nippon Shinyaku for Tadekinig alfa for an ultra-rare autoimmune disease
Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic ...
Nippon Life Is Said to Revamp Overseas Business After M&A Spree
Nippon Life Insurance Co. will reorganize its overseas operations to better monitor risks from its recent spate of ...